Table 2.
Demographic and clinical characteristics of 117 patients with preexisting ITP who received at ≥1 dose of a SARS-CoV-2 vaccine
| Characteristic | Mean ± SD, median [IQR], or n (%) | No. available for analysis |
|---|---|---|
| Age | 62.5 ± 16.9 | 116 |
| Gender | ||
| Male | 43 (37.8) | 117 |
| Female | 74 (62.2) | 74 (62.2) |
| Duration of ITP diagnosis (y) | 12 [4-23] | 97 |
| No. of previous ITP treatments | ||
| None | 6 (8.1) | 74 |
| Medical treatments* | 3 [2-4] | 75 |
| Rituximab | 41 (40.6) | 101 |
| Splenectomy | 25 (20.7) | 117 |
| Current ITP treatment | ||
| TPO-RA only | 47 (40.2) | 117 |
| Corticosteroid only | 4 (3.4) | |
| Other single-agent therapies† | 5 (4.3) | |
| TPO-RA + corticosteroid | 5 (4.3) | |
| TPO-RA + IVIG + mycophenolate | 3 (2.6) | |
| TPO-RA + ibrutinib | 2 (1.7) | |
| Corticosteroid + mycophenolate | 2 (1.7) | |
| TPO-RA + corticosteroid + mycophenolate | 1 (0.8) | |
| No current treatment and platelets <150 × 109/L | 32 (27.4) | |
| No current treatment and platelets ≥150 × 109/L | 16 (13.7) | |
| Comorbidities | ||
| Autoimmune hemolytic anemia | 10 (11.6) | 86 |
| Other autoimmune disease | 31 (36) | |
| Vaccine manufacturer | ||
| Moderna | 48 (42.1) | 114 |
| Pfizer-BioNTech | 53 (46.5) | |
| Janssen | 4 (3.5) | |
| Oxford-AstraZeneca | 9 (7.9) |
*
Only patients who have received treatments for ITP are included. Medical treatments includes rituximab.
†
Fostamatinib (n = 2), azathioprine (n = 1), dapsone (n = 1), and cyclosporine (n = 1).